Syndecan‐1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation
暂无分享,去创建一个
A. Miyauchi | Y. Takamura | H. Yoshida | A. Miya | F. Matsuzuka | N. Matsuura | Y. Ito | K. Kobayashi | K. Nakano | K. Kuma | T. Yokozawa
[1] M. Salmivirta,et al. Syndecan family of cell surface proteoglycans: Developmentally regulated receptors for extracellular effector molecules , 1995, Experientia.
[2] Z. Baloch,et al. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. , 2002, Archives of pathology & laboratory medicine.
[3] A. Miyauchi,et al. Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid , 2002, British Journal of Cancer.
[4] J. Watari,et al. Reduced Expression of Syndecan‐1 Affects Metastatic Potential and Clinical Outcome in Patients with Colorectal Cancer , 2001, Japanese journal of cancer research : Gann.
[5] T. Nemoto,et al. Loss of Syndecan‐1 and Increased Expression of Heparanase in Invasive Esophageal Carcinomas , 2001, Japanese journal of cancer research : Gann.
[6] K. Kikuchi,et al. Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor. , 2001, Lung cancer.
[7] C. Haglund,et al. Epithelial and stromal syndecan‐1 expression as predictor of outcome in patients with gastric cancer , 2001, International journal of cancer.
[8] R. Lloyd. Distinguishing benign from malignant thyroid lesions: Galectin 3 as the latest candidate , 2001, Endocrine pathology.
[9] S. Nordling,et al. A prognostic value of syndecan-1 in gastric cancer. , 2000, Anticancer research.
[10] S. Grénman,et al. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. , 1999, Gynecologic oncology.
[11] M. J. Stanley,et al. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. , 1999, American journal of clinical pathology.
[12] A. Forbes,et al. Changes in the expression of syndecan-1 in the colorectal adenoma–carcinoma sequence , 1999, Virchows Archiv.
[13] B. Weyn,et al. Syndecan‐1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome , 1998, The Journal of pathology.
[14] M. Filla,et al. The cell surface proteoglycan syndecan‐1 mediates fibroblast growth factor‐2 binding and activity , 1998, Journal of cellular physiology.
[15] M. J. Stanley,et al. Heparan Sulfate Proteoglycans as Adhesive and Anti-invasive Molecules SYNDECANS AND GLYPICAN HAVE DISTINCT FUNCTIONS* , 1998 .
[16] A. Kovatich,et al. Keratin subsets in papillary and follicular thyroid lesions , 1997, Virchows Archiv.
[17] K. Nackaerts,et al. Heparan sulfate proteoglycan expression in human lung‐cancer cells , 1997, International journal of cancer.
[18] G Brabant,et al. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. , 1997, Cancer research.
[19] M. Jalkanen,et al. Syndecan-1: a new prognostic marker in laryngeal cancer. , 1997, Acta oto-laryngologica.
[20] Y. Kohgo,et al. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. , 1997, International journal of cancer.
[21] R. Gallo,et al. Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin. , 1996, The Journal of investigative dermatology.
[22] M. Jalkanen,et al. The role of syndecan-1 in malignancies. , 1996, Annals of medicine.
[23] A. Brunet,et al. The Mouse p44 Mitogen-activated Protein Kinase (Extracellular Signal-regulated Kinase 1) Gene , 1995, The Journal of Biological Chemistry.
[24] W. Birchmeier,et al. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. , 1995, The Journal of clinical endocrinology and metabolism.
[25] R. Sanderson,et al. Expression of syndecan-1 inhibits cell invasion into type I collagen. , 1994, The Journal of biological chemistry.
[26] H. Joensuu,et al. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. , 1994, British Journal of Cancer.
[27] M. Jalkanen,et al. Suppression of tumor cell growth by syndecan-1 ectodomain. , 1994, The Journal of biological chemistry.
[28] G. Brabant,et al. E-cadherin: a differentiation marker in thyroid malignancies. , 1993, Cancer research.
[29] J. Woodliff,et al. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. , 1993, Blood.
[30] T. Seyama,et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. , 1992, Cancer research.
[31] M. Laato,et al. Induced expression of syndecan in healing wounds , 1991, The Journal of cell biology.
[32] M. Jalkanen,et al. Cell surface proteoglycan associates with the cytoskeleton at the basolateral cell surface of mouse mammary epithelial cells , 1986, The Journal of cell biology.
[33] A. Sakamoto,et al. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high‐risk group of papillary and follicular carcinomas , 1983, Cancer.
[34] N. Samaan,et al. Anaplastic carcinoma of the thyroid. A review of 84 cases of spindle and giant cell carcinoma of the thyroid , 1978 .